PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Aetion and Cegedim expand real-world data partnership

Aetion and Cegedim Health Data have expanded their collaboration with a new three-year partnership focused on facilitating access to Cegedim’s anonymised real-world data through Aetion’s evidence platform.
Currently, Cegedim’s database covers the UK, France, Spain, Italy, Belgium and Romania with further plans to include data from Germany.
In 2020, the two partners announced an initial collaboration to integrate Cegedim’s ‘THIN’ European real-world data into Aetion’s evidence platform (AEP).
AEP can be used to analyse real-world date, including claims, electronic health records, registries and clinical trial data to produce ‘scientifically-validated’ real world evidence (RWE) on the safety, effectiveness and value of medical interventions.
Following the first year of their partnership, Aetion and Cegedim will further collaborate to enable cleints to monitor the utilisation, safety and effectiveness of medicines at scale across Europe.
“The Aetion-Cegedim Health Data partnership advances access to pan-European data sources for real-world evidence research and enables us to help our customers navigate data privacy regulations and the heterogeneity of data across countries,” said Carolyn Magill, chief executive officer of Aetion.
“Combining Cegedim Health Data’s THIN database with the AEP is critical as manufacturers, regulators, and HTAs work to assess the utilisation, safety, and effectiveness of interventions, as well as the long-term impact of COVID-19,” she added.
“The COVID-19 pandemic has highlighted the relevance of real-world patient data and has changed health sector attitudes on the importance of recent, regularly updated data to help monitor patient symptom trends, as well as the safety and efficacy of new treatments for the benefit of public health,” commented Gilles Paubert, global head of Cegedim Health Data.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026